• Users Online: 112
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
Year : 2019  |  Volume : 4  |  Issue : 2  |  Page : 37-42

Clinical progress of cell therapy in treating age-related macular degeneration

1 Institute of Burn Research, Wuxi Third People's Hospital, Wuxi, Jiangsu Province, China
2 Eyecure Therapeutics Inc. (Jiangsu), Wuxi, Jiangsu Province, China

Correspondence Address:
Ling Diao
Institute of Burn Research, Wuxi Third People's Hospital, Wuxi, Jiangsu Province
Pan-Feng Fang
Eyecure Therapeutics Inc. (Jiangsu), Wuxi, Jiangsu Province
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2542-3975.260958

Rights and Permissions

Age-related macular degeneration is a retinal degenerative lesion caused by cell atrophy and dysfunction of retinal pigment epithelium. The degeneration of retinal pigment epithelium cells further leads to the apoptosis of photoreceptor cells, causes vision deterioration and eventually even blindness. Age-related macular degeneration is one of the top three retinal diseases causing blindness in the world. In recent years, exogenous retinal pigment epithelium cell therapy has emerged as a breakthrough treatment for age-related macular degeneration disease. In this review, we will briefly introduce the policies and regulations of cell therapy and discuss the clinical progress in the treatment of age-related macular degeneration using retinal pigment epithelium cells.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded313    
    Comments [Add]    

Recommend this journal